An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

The EuroVacc 02 phase I trial has evaluated the safety and immunogenicity of a prime-boost regimen comprising recombinant DNA and the poxvirus vector NYVAC, both expressing a common immunogen consisting of Env, Gag, Pol, and Nef polypeptide domain from human immunodeficiency virus (HIV)-1 clade C is...

Descripción completa

Detalles Bibliográficos
Autores principales: Harari, Alexandre, Bart, Pierre-Alexandre, Stöhr, Wolfgang, Tapia, Gonzalo, Garcia, Miguel, Medjitna-Rais, Emmanuelle, Burnet, Séverine, Cellerai, Cristina, Erlwein, Otto, Barber, Tristan, Moog, Christiane, Liljestrom, Peter, Wagner, Ralf, Wolf, Hans, Kraehenbuhl, Jean-Pierre, Esteban, Mariano, Heeney, Jonathan, Frachette, Marie-Joelle, Tartaglia, James, McCormack, Sheena, Babiker, Abdel, Weber, Jonathan, Pantaleo, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2008
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234371/
https://www.ncbi.nlm.nih.gov/pubmed/18195071
http://dx.doi.org/10.1084/jem.20071331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234371/
https://www.ncbi.nlm.nih.gov/pubmed/18195071
http://dx.doi.org/10.1084/jem.20071331

Ejemplares similares